Biosearch Technologies Expands Licensing of QIAGEN Scorpions® Patents

Biosearch Technologies today announces that it has entered into a new license relationship with QIAGEN (NASDAQ: QIA, Frankfurt Prime Standard) providing broad commercialisation rights to Scorpions Primers.  This agreement allows Biosearch the right to manufacture, catalog, and sell Scorpions primer assays into the research, applied, and infectious disease testing markets.

To read the entire story, read the full press release" target="_self">read the full press release.